{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:46:36Z","timestamp":1795013196330,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009795","name":"Pancreatic Cancer UK","doi-asserted-by":"publisher","award":["PCUK H3R00510"],"award-info":[{"award-number":["PCUK H3R00510"]}],"id":[{"id":"10.13039\/100009795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R01695X\/1"],"award-info":[{"award-number":["MR\/R01695X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["H3R00580"],"award-info":[{"award-number":["H3R00580"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.nucmedbio.2022.108312","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T21:07:54Z","timestamp":1672175274000},"page":"108312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy"],"prefix":"10.1016","volume":"116-117","author":[{"given":"Gianluca","family":"Destro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung Ying","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mosley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Guibbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Gouverneur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2022.108312_bb0005","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ijrobp.2015.07.2284","article-title":"Radiation therapy intensification for solid tumors: a systematic review of randomized trials","volume":"93","author":"Kosj","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0010","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3390\/ph14050447","article-title":"Current prospects for treatment of solid tumors via photodynamic, photothermal, or ionizing radiation therapies combined with immune checkpoint inhibition (A review)","volume":"14","author":"Anand","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0015","first-page":"11","article-title":"Clinical and preclinical outcomes of combining targeted therapy with radiotherapy, front","author":"Elbanna","year":"2021","journal-title":"Oncologia"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41936-019-0083-5","article-title":"Recent advances in radiotherapy and its associated side effects in cancer\u2014a review","volume":"80","author":"Mohan","year":"2019","journal-title":"J Basic Appl Zool"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/ijms17010033","article-title":"Targeted radionuclide therapy of human tumors","volume":"17","author":"Gudkov","year":"2016","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0030","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.3390\/cancers3043838","article-title":"Targeted radionuclide therapy","volume":"3","author":"Ersahin","year":"2011","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/157016310793360657","article-title":"Targeting the nucleus: an overview of auger-electron radionuclide therapy","volume":"7","author":"Cornelissen","year":"2010","journal-title":"Curr Drug Discov Technol"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0040","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/09553000400017663","article-title":"The amazing world of auger electrons","volume":"80","author":"Kassis","year":"2004","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2021.03.012","article-title":"Targeted auger electron-emitter therapy: radiochemical approaches for thallium-201 radiopharmaceuticals","volume":"98","author":"Rigby","year":"2021","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0050","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fphar.2020.00170","article-title":"Poly(ADP-ribose)polymerase (PARP) inhibitors and radiation therapy","volume":"11","author":"Jannetti","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0055","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0060","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/annonc\/mdq322","article-title":"A review of PARP inhibitors: from bench to bedside","volume":"22","author":"Underhill","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0065","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1158\/1538-7445.AM10-5771","article-title":"Molecular radiation therapy: targeting DNA damage response proteins","volume":"70","author":"Cornelissen","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0070","first-page":"5","article-title":"Radioiodinated PARP1 tracers for glioblastoma imaging","volume":"46","author":"Salinas","year":"2015","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0075","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1158\/1078-0432.CCR-19-2440","article-title":"Targeted brain tumor radiotherapy using an auger emitter","volume":"26","author":"Pirovano","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0080","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2967\/jnumed.117.205054","article-title":"PARP-1-targeted radiotherapy in mouse models of glioblastoma","volume":"59","author":"Jannetti","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0085","doi-asserted-by":"crossref","first-page":"850","DOI":"10.2967\/jnumed.119.233965","article-title":"PARP-1-targeted auger emitters display high-LET cytotoxic properties in vitro but show limited therapeutic utility in solid tumor models of human neuroblastoma","volume":"61","author":"Lee","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0090","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1158\/0008-5472.CAN-16-0416","article-title":"A radiotracer strategy to quantify PARP-1 expression in vivo provides a biomarker that can enable patient selection for PARP inhibitor therapy","volume":"76","author":"Makvandi","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0095","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1158\/1535-7163.MCT-18-0837","article-title":"Targeting PARP-1 with alpha-particles is potently cytotoxic to human neuroblastoma in preclinical models","volume":"18","author":"Makvandi","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0100","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/cancers14010230","article-title":"Auger emitter conjugated PARP inhibitor for therapy in triple negative breast cancers: a comparative in-vitro study","volume":"4","author":"Sankaranarayanan","year":"2022","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0105","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2967\/jnumed.118.213223","article-title":"PET imaging of PARP expression using 18F-olaparib","volume":"60","author":"Wilson","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0110","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s11307-020-01497-6","article-title":"[18F]AZD2461, an insight on difference in PARP binding profiles for DNA damage response PET imaging","volume":"20","author":"Guibbal","year":"2020","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0115","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1021\/acs.orglett.1c02770","article-title":"Copper-mediated radiosynthesis of [18F]Rucaparib","volume":"23","author":"Chen","year":"2021","journal-title":"Org Lett"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0120","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1007\/s00259-022-05835-4","article-title":"Imaging PARP with [18F]rucaparib in pancreatic cancer models","volume":"49","author":"Chan","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0125","article-title":"Correction to: Closing the gap between 19F and 18F chemistry (EJNMMI Radiopharmacy and Chemistry, 2021;6:33, 10.1186\/s41181-021-00143-y)","volume":"7","author":"Ajenjo","year":"2022","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s41181-021-00143-y","article-title":"Closing the gap between 19F and 18F chemistry","volume":"6","author":"Ajenjo","year":"2021","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0135","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1078-0432.CCR-20-2766","article-title":"PARP inhibitors in cancer diagnosis and therapy","volume":"27","author":"Chan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0140","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3390\/cancers14051129","article-title":"DNA repair enzyme Poly(ADP-Ribose) polymerase 1\/2 (PARP1\/2)-targeted nuclear imaging and radiotherapy","volume":"14","author":"Nguyen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0145","series-title":"In vitro targeted radionuclide therapy studies of a PARP-targeted Meitner-Auger electron emitting radiopharmaceutical","author":"Hoffman","year":"2022"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0150","first-page":"303","article-title":"Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments","volume":"35","author":"Goddu","year":"1994","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0155","doi-asserted-by":"crossref","first-page":"13277","DOI":"10.1039\/C6CC07417K","article-title":"Radiosynthesis of SPECT tracers: via a copper mediated 123I iodination of (hetero)aryl boron reagents","volume":"52","author":"Wilson","year":"2016","journal-title":"Chem Commun"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0160","doi-asserted-by":"crossref","first-page":"10246","DOI":"10.1021\/acs.jmedchem.1c00668","article-title":"The effects on lipophilicity of replacing oxygenated functionality with their fluorinated bioisosteres","volume":"64","author":"Glyn","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0165","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1021\/jm980273t","article-title":"Resistance-modifying agents. 5.1 synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)","volume":"41","author":"Griffin","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22084203","article-title":"Differences in parp inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy","volume":"22","author":"Valabrega","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0175","series-title":"Pure and Applied Chemistry","first-page":"360","article-title":"Cu(I)\/Cu(III) catalytic cycle involved in Ullmann-type cross-coupling reactions","volume":"345","author":"Ribas","year":"2014"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0180","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.aat4133","article-title":"A radical approach to the copper oxidative addition problem: Trifluoromethylation of bromoarenes","volume":"360","author":"Le","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0185","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1021\/ol500310u","article-title":"Copper-catalyzed suzuki-miyaura coupling of arylboronate esters: transmetalation with (PN)CuF and identification of intermediates","volume":"16","author":"Gurung","year":"2014","journal-title":"Org Lett"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0190","doi-asserted-by":"crossref","first-page":"21058","DOI":"10.1073\/pnas.2011831117","article-title":"HARC as an open-shell strategy to bypass oxidative addition in Ullmann-Goldberg couplings","volume":"117","author":"Lavagnino","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0195","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13550-022-00940-9","article-title":"Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F]olaparib in mouse models of glioma","volume":"12","author":"Chan","year":"2022","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0200","first-page":"8","article-title":"Estimating the relative biological effectiveness of auger electron emitter 123I in human lymphocytes","author":"Fourie","year":"2020","journal-title":"Front Phys."},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0205","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2307\/3577411","article-title":"Radiotoxicity of 5-[123I]iodo-2'-deoxyuridine in V79 cells: a comparison with 5-[125I]iodo-2'-deoxyuridine","volume":"118","author":"Makrigiorgos","year":"1989","journal-title":"Radiat Res"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0210","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1021\/acs.jmedchem.5b00680","article-title":"Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): a potent, orally available, and highly selective PARP-1 inhibitor for cancer therapy","volume":"58","author":"Papeo","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25246029","article-title":"PARP theranostic auger emitters are cytotoxic in BRCA mutant ovarian cancer and viable tumors from ovarian cancer patients enable ex-vivo screening of tumor response","volume":"25","author":"Riad","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0220","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40658-021-00407-1","article-title":"Evaluation of Iodine-123 and Iodine-131 SPECT activity quantification: a Monte Carlo study","volume":"8","author":"Morphis","year":"2021","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0225","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1007\/s00259-006-0187-2","article-title":"Auger radiation targeted into DNA: a therapy perspective","volume":"33","author":"Buchegger","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-019-0075-2","article-title":"Auger electrons for cancer therapy \u2013 a review","volume":"4","author":"Ku","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2022.108312_bb0235","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.3390\/molecules27165231","article-title":"Radiopharmaceutical treatments for cancer therapy, radionuclides characteristics, applications, and challenges","volume":"27","author":"Salih","year":"2022","journal-title":"Molecules"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980512202306X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980512202306X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:49:51Z","timestamp":1778575791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096980512202306X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":47,"alternative-id":["S096980512202306X"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2022.108312","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv-2022-rtc8h","asserted-by":"object"}]},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2022.108312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108312"}}